<DOC>
	<DOCNO>NCT01487785</DOCNO>
	<brief_summary>This phase Ib study include two phase : dose escalation phase safety expansion phase . During dose escalation phase , successive cohort eligible patient ( minimum 3 maximum 6 evaluable patient per cohort ) receive increase oral dos LDE225 administer continuous daily ( QD ) dose combination gemcitabine . This phase study determine maximum tolerate dose ( MTD ) and/ recommend dose expansion ( RDE ) LDE225 administer combination gemcitabine locally advance metastatic pancreatic adenocarcinoma patient . During safety expansion phase , MTD LDE225 establish , additional patient enrol treated MTD LDE225 combination gemcitabine order evaluate safety , tolerability explore potential efficacy combine treatment patient locally advance metastatic pancreatic adenocarcinoma .</brief_summary>
	<brief_title>Dose-escalation , Safety Study LDE225 Gemcitabine Locally Advanced Metastatic Pancreatic Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients locally advance metastatic pancreatic adenocarcinoma previously treat progressed despite chemotherapy Performance status 0 1 per WHO classification Adequate hematologic , renal liver function Adequate blood creatine kinase value ( CK &lt; 1.5ULN ) Treatment prior radiotherapy Pancreatic cancer potentially curable surgery Women childbearing potential unless use highly effective method contraception Other protocoldefined inclusion/exclusion criterion may apply Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>LDE225</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>locally advanced</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>